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Background-—Management of antithrombotic agents after implantable cardioverter defibrillator implantation is challenging,
particularly among patients with atrial fibrillation and coronary artery disease.
Methods and Results-—Using data from National Cardiovascular Data Registry Implantable Cardioverter Defibrillator
RegistryTM linked with Medicare claims data, we identified 25 180 patients with atrial fibrillation and coronary artery disease
who underwent implantable cardioverter defibrillator implantation. Patients were categorized into 5 different groups according
to antithrombotic agents prescribed at discharge (any 1 antiplatelet agent [A, n=6538], dual antiplatelet therapy [DA, n=3414],
warfarin [n=5264], warfarin+A [n=7994], warfarin+DA [n=1970]). We assessed the primary outcomes occurring within 30 days
of hospital discharge. Combinations of DA (adjusted hazard ratio [HR]: 1.39; 95% CI: 1.03 to 1.87), warfarin+A (adjusted HR:
1.32; 95% CI: 1.03 to 1.69), and warfarin+DA (adjusted HR: 2.03; 95% CI: 1.49 to 2.77) were associated with a higher
bleeding risk. The risk of major adverse cardiovascular events was higher in patients discharged with A (adjusted HR: 1.69;
95% CI: 1.33 to 2.16), DA (adjusted HR: 2.17; 95% CI: 1.66 to 2.83), and DA+warfarin (adjusted HR: 1.61; 1.16 to 2.24).
There was no association between postdischarge antithrombotic agents and thromboembolic events or device-related
complications.
Conclusions-—Short-term bleeding risk and major adverse cardiovascular events differ with usage patterns of antithrombotic
agents, while the risk of thromboembolic events and device-related complications is relatively constant. These data may help
clinicians balance risks and benefits when choosing antithrombotic therapy following implantable cardioverter defibrillator
implantation. ( J Am Heart Assoc. 2015;4:e001331 doi: 10.1161/JAHA.114.001331)
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Implantable cardioverter-defibrillators (ICDs) improve sur-vival in patients at high risk of sudden cardiac death, but device implantation carries a significant risk of bleedingcomplications.1 Although multiple factors influence bleeding
risk, postprocedural antithrombotic therapy is likely to play a
significant role, particularly among patients who require
multiple agents due to atrial fibrillation (AF) and coronary
artery disease (CAD).2,3 However, this may substantially
increase the risk of bleeding around the time of the
procedure.2,3 Decisions regarding antithrombotic therapy
require balancing the competing risks of bleeding complica-
tions and thromboembolic events (TEs). However, currently
there are no guidelines for the management of antithrombotic
therapy for patients with AF and CAD after ICD implantation.
The lack of guidelines may reflect incomplete knowledge
about the association between different antithrombotic
agents and short-term outcomes after ICD implantation.
At present, patterns of use of postprocedural antithrom-
botic agents and their association with clinical outcomes have
not been described. We therefore set out to determine
patterns of utilization of antiplatelet agents and warfarin and
the associated early, short-term risks of bleeding, TEs, and
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device-related complications in patients with AF and CAD
who are discharged on antithrombotic agents using the
National Cardiovascular Data Registry’s (NCDR’s) ICD
RegistryTM. The registry collects data on patients’ postdis-
charge antithrombotic medications and when linked with
Medicare claims data, it provides an opportunity to evaluate
outcomes associated with antithrombotic agents following
ICD implantation.
Methods
Data Source
Patients with ICD implantation were enrolled from the
registry. The registry, which is cosponsored by the American
College of Cardiology and the Heart Rhythm Society, has been
previously described.4 The registry was established in April
2006 and has been funded by a combination of hospital fees
and grants from both device companies and payers. Hospitals
are required to submit data on all Centers for Medicare and
Medicaid Services patients who receive an ICD for primary
prevention of sudden cardiac death.5 However, more than
75% of hospitals report data on all ICD implantations
(irrespective of indication and payer), and these hospitals
submit more than 88% of all cases in the registry.4
The registry collects more than 130 data elements at the
time of initial ICD implantation, device upgrade, and device
replacement. Clinical, demographic, procedural information,
and discharge medications are collected in addition to
information about adverse events until the time of discharge
using standardized data elements and definitions. Data are
submitted by participating hospitals using certified software.
Data quality is examined using a formal Data Quality
Reporting and audit process.4,6 Longitudinal outcomes were
obtained by linking registry files with Medicare inpatient fee-
for-service claims using probabilistic matching, as previously
described.7
Patient Population
All admissions from January 2006 through December 2009
that could be matched to Centers for Medicare and Medicaid
Services Medicare fee-for-service claims data were identified.
We restricted the population to patients with a history of AF
and CAD. We defined CAD as having 1 of the following: (1)
ischemic heart disease, (2) previous myocardial infarction, (3)
coronary artery bypass grafting, or (4) previous percutaneous
coronary intervention (PCI). Patients were excluded if they
were not enrolled in the Medicare fee-for-service; had a
previous ICD or pacemaker; did not have 3 months of follow-
up; had unknown medications on discharge; had experienced
bleeding complications during the hospitalization for ICD
implantation; or were not discharged on any medications
under evaluation.
Postdischarge Medication Groups
We divided patients into 5 groups based on the postdischarge
antiplatelet and anticoagulant agents. These groups included
patients with (1) warfarin, (2) 1 antiplatelet agent (A), (3) dual
antiplatelet agents (DA), (4) warfarin and A; and (5) warfarin
and DA. The antiplatelet agents included in the analysis were
aspirin and clopidogrel/ticlodipine. Patients discharged with-
out any antithrombotic agents or with missing information
about discharge medications were not included in our
analysis.
Endpoints and Definitions
The outcomes for this analysis were bleeding, TEs, major
adverse cardiovascular events (MACE), and device-related
complications. We focused our primary evaluation on out-
comes 30 days postdischarge to minimize the effect of
medication changes postdischarge. In our secondary analysis,
we evaluated outcomes 90 days following discharge. We
identified bleeding, MACE, TEs, and device-related complica-
tions based on commonly used ICD-9-CM diagnosis and
procedure-related codes (Table 1).1,5,8,9 Complications that
could be attributable to device implantation were considered
device-related complications.1
Statistical Analysis
Baseline characteristics and outcomes were compared
between patients according to postdischarge antithrombotic
medication groups using F tests in ANOVA model analysis for
continuous variables and v2 tests in frequency table analysis
for categorical variables. A Cox proportional hazards model
was used to estimate the adjusted risk of the antithrombotic
medication groups on bleeding, TEs, and device-related
complications after accounting for differences in patient and
procedural characteristics. Characteristics that we adjusted
for included gender, race, New York Heart Association
Functional Class, prior myocardial infarction, chronic lung
disease, renal failure requiring dialysis, ejection fraction,
creatinine, and CHADS2VASC score. Hazard ratios (HRs) for
each postdischarge medication group were calculated after
adjusting for the baseline covariates. Multivariable logistic
regression model was used to identify factors associated with
the decision to discharge patients with warfarin.
We evaluated the association between the treatment
groups and outcomes using inverse probability–weighted
estimators incorporating propensity scores to compare treat-
ment groups. The propensity scores were calculated based on
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Table 1. ICD-9 Codes Used for Defining Thromboembolic and Bleeding Events
Thromboembolic events
Cerebral occlusion, nonhemorrhagic stroke, or transient
ischemic attack
433.x1, 434.x1, 435.x, 436, 437.1x, 437.9x,
Arterial peripheral embolus 444.x, 445.x
Deep vein thrombosis, pulmonary embolism, or other venous
thrombosis
415.1x, 451.1x, 451.2, 451.81, 451.9, 452.x, 453.x
Bleeding events
Gastrointestinal
Control of hemorrhage and suture of ulcer of stomach or
duodenum
44.4x
Esophageal 530.82
Ulcer 531.0x, 531.2x, 531.4x, 531.6x, 532.0x, 532.2x, 532.4x, 532.6x, 533.0x, 533.2x, 533.4x, 533.6x, 534.0x, 534.2x,
534.4x, 534.6x
Gastritis and duodenitis with hemorrhage 535.x1
Bleeding of stomach or duodenum due to vascular
abnormalities
537.83, 537.84
Bleeding of intestine due to vascular abnormality 569.85, 569.86
Rectum 569.3x
Unspecified 578.x
Cerebrovascular
Subarachnoid hemorrhage 430.x
Intracerebral hemorrhage 431.x
Intracranial hemorrhage 432.x
Bleeding related to procedure
Hematoma 998.1x
Tamponade/pericardiocentesis/pericardiotomy 423.3, 37.0, 37.12
Hemopericardium 423.0
Hemarthrosis 719.1x
Hematuria 599.7
Vaginal 626.2, 626.6, 626.8, 627.0, 627.1
Hemoptysis 786.3
Epistaxis 784.7
Hemorrhage not otherwise specified 459.0
Device-related complications
Other incision with drainage of skin and subcutaneous tissue 86.04
Other skin incision of subcutaneous tissue 86.09
Mechanical complications with system revision 996.0, 996.00, 996.01, 996.02, 996.03, 996.04
System revision 37.75, 37.77, 37.79, 37.97, 37.99, 00.52
Device-related infection 996.61
Pneumothorax/chest tube 512.1, 34.04, 34.06, 34.09
Device-related bleeding
Hemothorax 511.89
Hematoma 998.1x
Tamponade/pericardiocentesis/pericardiotomy 423.3, 37.0, 37.12
Hemopericardium 423.0
Major adverse cardiovascular events
Death
Myocardial infarction 410.X1
Percutaneous coronary intervention 36.00, 36.06, 36.07, and 36.09
Coronary artery bypass grafting 36.10-19
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a logistic regression model for the use of warfarin, which was
supposed to make the treatment groups more balanced.
Inverse probability–weighted estimators require fewer distri-
butional assumptions and handle censored data.10 Adjusted
HRs were calculated according to the inverse probability–
weighted approach of Cole and Hernan.11 Proportional-
hazards assumption was tested using the graph of the log
(log [survival]) versus log of survival time and Schoenfeld
residuals on the functions of time. No parallel curves or a
nonzero slope indicated violation of the proportional-hazards
assumption. The assumption of proportionality was tested and
met for the Cox proportional hazards analyses.
The statistical significance of differences among strata was
tested in survival models accounting for matched groups. We
did not account for clustering within hospitals for the final
analysis. All statistical tests were 2-sided with a significance
threshold of P<0.05. All analyses were performed using the
statistical packages of SAS version 9.3 (SAS Institute Inc).
Analyses of the ICD Registry were approved by the Yale
Human Investigation Committee.
Results
The merged data set between the registry and Centers for
Medicare and Medicaid Services Medicare claims comprises
185 574 patients between January 2006 and December
2009. Patients were excluded sequentially if they did not have
a full 3-month follow-up (n=4840); had a previous ICD
(n=55 822), previous pacemaker (n=19 214); unknown med-
ications (n=1025); no history of AF (n=67 536); epicardial
leads (n=534); bleeding complications in hospital (n=642); no
history of CAD (n=7511); and were not in the considered
medication subgroups (n=3270). There were 25 180 patients
from 1218 sites who met our inclusion criteria and were
included in the study population (Figure 1).
Overall, there were differences in cerebrovascular disease,
diabetes, and hypertension among patients discharged with
different antithrombotic agent combinations. Baseline char-
acteristics of patients according to medications postdischarge
are summarized in Table 2. There was substantial variation in
postdischarge medications according to hospital geographic
location. There were also differences according to the
community served and profit type of hospitals (Table 3).
The proportion of patients discharged on warfarin varied
only modestly by the patient stroke risk as assessed by the
CHADS2VASC score (Figure 2). A substantial proportion of
patients with CHADS2VASC ≥2 were not discharged with
warfarin (9952/25 180, 39.5%). In multivariable analysis,
we assessed factors associated with patients being dis-
charged on warfarin. These included ischemic heart disease,
nonischemic cardiomyopathy, sinus node dysfunction, con-
gestive heart failure with New York Heart Association II or III
symptoms, previous myocardial infarction, coronary artery
bypass grafting or PCI, history of valvular surgery, diabetes
mellitus, hypertension, renal failure requiring dialysis, elevated
systolic blood pressure, elevated blood urea nitrogen levels,
QRS duration, and CHADS2VASC score. The risk of bleeding
assessed by CHADS2VASC score was not a predictor of
discharge warfarin (Figure 3).
There were 10 669 patients with a history of PCI. A higher
proportion of patients were discharged on DA if their PCI had
been performed within 3 months of the ICD implantation
(36.0%). Among patients whose PCI was performed more than
3 months of the ICD implantation, a higher proportion of
patients were treated with warfarin and A (30.7%).
Bleeding, TEs, Device-Related Complications, and
MACE
Thirty-day outcomes
Overall, 575 (2.3%) bleeding, 642 (2.5%) MACE, 356 (1.4%)
TEs, and 605 (2.4%) device-related complications were
observed 30 days following hospital discharge (Table 4).
There were 204 (0.8%) device-related bleeding events, which
included 176 (0.7%) hematomas. Patients discharged on
warfarin+DA had the highest number of bleeding events
(3.6%) compared to those discharged on A (2.2%), DA (2.5%),
warfarin+A (2.4%), or warfarin (1.7%). Device-related bleeding
was more common in patients discharged with warfarin+DA
(1.1%) compared to A (0.7%), DA (0.9%), warfarin+A (1.0%), or
warfarin (0.6%). Patients discharged on warfarin alone had the
lowest rates of MACE (1.8%), compared to those discharged
on A (3.0%), DA (3.9%), warfarin+A (2.0%), and warfarin+DA
(2.9%). Patients discharged with DA had the highest rates of
TEs (2.0%) compared to those discharged on A (1.4%),
warfarin (1.5%), warfarin+A (1.2%), or warfarin+DA (1.1%).
There were 1970 (7.8%) patients discharged with triple
therapy. In multivariable analysis, combinations of DA,
warfarin+A, and warfarin+DA were independently associated
with higher bleeding risk when compared with warfarin alone
(Table 5). Specifically, warfarin+A and warfarin+DA were
associated with higher device-related bleeding. Patients
discharged with A, DA, and warfarin+DA were associated
with a higher risk of MACE. The risk of TEs and device-related
complications did not vary across groups. There were no
differences in bleeding and TEs, across CHADS2VASC scores,
among patients treated and untreated with warfarin (Table 6).
Ninety-day outcomes
There were 1147 (4.6%) bleeding, 705 (2.8%) TEs, 1072 (4.3%)
device-related complications, and 1766 (7.0%) MACE
observed 90 days following discharge (Table 4). There were
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299 (1.2%) device-related bleeding events, which included
252 (1.0%) hematomas. Patients discharged on warfarin and
DA had the highest number of subsequent bleeding events
(7.4%) compared to those discharged on A (4.0%), DA (4.9%),
warfarin+A (4.7%), or warfarin (3.7%). Patients discharged with
warfarin+A had the lowest rates of MACE (5.7%), compared to
those discharged on A (7.7%), DA (9.9%), warfarin (6.0%), and
warfarin+DA (7.6%). Patients discharged with DA had the
highest number of TEs (3.7%) compared to those discharged
on A (3.1%), warfarin (2.7%), warfarin+A (2.4%), or warfa-
rin+DA (2.4%). In multivariable analysis, combinations of DA,
warfarin+A, and warfarin+DA were independently associated
with higher bleeding risk when compared with warfarin alone
(Table 5). The risk of device-related bleeding events was
higher in patients discharged with DA, warfarin+A, and
warfarin+DA. Furthermore, patients discharged with DA and
warfarin+A had a higher risk of device-related complications.
Patients discharged with A, DA, and warfarin+DA were
associated with a higher risk of MACE. The risk of TEs did
not vary across groups. There was a higher risk of TEs in
patients with intermediate (3 to 5) and high (≥6) CHADS2-
VASC scores who were not treated with warfarin compared to
those treated with warfarin (Table 6). Furthermore, there was
a higher risk of bleeding in patients with high (≥6)
CHADS2VASC scores who were treated with warfarin
(Table 6).
Figure 1. Selection of patients from the NCDR ICD Registry. AF indicates atrial fibrillation; CAD, coronary
artery disease; CMS, Centers for Medicare and Medicaid Services; ICD, implantable cardioverter
defibrillator; NCDR, National Cardiovascular Data RegistryTM; PPM, permanent pacemaker.
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Table 2. Baseline Characteristics
Total (n=25 180) A (n=6538) DA (n=3414)
Warfarin
(n=5264)
A+Warfarin
(n=7994)
DA+Warfarin
(n=1970)
Admission characteristics
Age: mean (SD)* 75.86.1 76.16.3 75.56.4 76.36.1 75.56.0 74.95.8
Female* 4964 (19.7%) 1375
(21.0%)
800 (23.4%) 1080 (20.5%) 1333 (16.7%) 376 (19.1%)
Race*
White 23 360
(92.8%)
6022
(92.1%)
3117
(91.3%)
4882 (92.7%) 7509 (93.9%) 1830 (92.9%)
Black 1029 (4.1%) 306 (4.7%) 160 (4.7%) 206 (3.9%) 274 (3.4%) 83 (4.2%)
History and risk factors
Syncope* 5160 (20.5%) 1494
(22.9%)
795 (23.3) 990 (18.8%) 1511 (18.9%) 370 (18.8%)
Family history of sudden death 866 (3.4%) 223 (3.4%) 124 (3.6%) 176 (3.3%) 272 (3.4%) 71 (3.6%)
Congestive heart failure* 20 631
(81.9%)
5243
(80.2%)
2657
(77.8%)
4464 (84.8%) 6654 (83.2%) 1613 (81.9%)
NYHA class—current status*
Class I 2253 (8.9%) 640 (9.8%) 366 (10.7%) 370 (7.0%) 700 (8.8%) 177 (9.0%)
Class II 8382 (33.3%) 2227
(34.1%)
1114
(32.6%)
1715 (32.6%) 2636 (33.0%) 690 (35.0%)
Class III 13 223
(52.5%)
3296
(50.4%)
1723
(50.5%)
2931 (55.7%) 4272 (53.4%) 1001 (50.8%)
Class IV 1322 (5.3%) 375 (5.7%) 211 (6.2%) 248 (4.7%) 386 (4.8%) 102 (5.2%)
Ischemic heart disease* 23 672
(94.0%)
6151
(94.1%)
3279
(96.0%)
4820 (91.6%) 7514 (94.0%) 1908 (96.9%)
Previous MI*
No 6844 (27.2%) 1737
(26.6%)
758 (22.2%) 1630 (31.0%) 2212 (27.7%) 507 (25.8%)
Yes—within 40 days of ICD implant 1942 (7.7%) 524 (8.0%) 440 (12.9%) 215 (4.1%) 540 (6.8%) 223 (11.3%)
Yes—more than 40 days since ICD
implant
15 203
(60.4%)
3976
(60.9%)
1945
(57.0%)
3239 (61.6%) 4924 (61.7%) 1119 (56.9%)
Yes—both within or more than 40 days 1163 (4.6%) 293 (4.5%) 269 (7.9%) 173 (3.3%) 310 (3.9%) 118 (6.0%)
Previous CABG* 13 681
(54.3%)
3706
(56.7%)
1614
(47.3%)
2839 (53.9%) 4616 (57.7%) 906 (46.0%)
Previous PCI
No 14 511
(57.6%)
4167
(63.7%)
1139
(33.4%)
3702 (70.3%) 4976 (62.2%) 527 (26.8%)
Yes—within the past 3 months 2103 (8.3%) 309 (4.7%) 757 (22.2%) 146 (2.8%) 385 (4.8%) 506 (25.7%)
Yes—greater than 3 months 8566 (34.0%) 2062
(31.5%)
1518
(44.5%)
1416 (26.9%) 2633 (32.9%) 937 (47.6%)
Cerebrovascular disease* 5327 (21.2%) 1293
(19.8%)
791 (23.2%) 1075 (20.4%) 1702 (21.3%) 466 (23.7%)
Chronic lung disease* 7055 (28.0%) 1960
(30.0%)
1014
(29.7%)
1447 (27.5%) 2088 (26.1%) 546 (27.7%)
Diabetes* 10 261
(40.8%)
2722
(41.6%)
1509
(44.2%)
1987 (37.7%) 3228 (40.4%) 815 (41.4%)
Hypertension* 20 799
(82.6%)
5416
(82.8%)
2922
(85.6%)
4216 (80.1%) 6576 (82.3%) 1669 (84.7%)
Continued
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Table 2. Continued
Total (n=25 180) A (n=6538) DA (n=3414)
Warfarin
(n=5264)
A+Warfarin
(n=7994)
DA+Warfarin
(n=1970)
Renal failure—dialysis* 1185 (4.7%) 381 (5.8%) 216 (6.3%) 211 (4.0%) 306 (3.8%) 71 (3.6%)
Diagnostics
EF %: mean (SD)* 28.09.6 28.510.0 28.810.4 27.39.0 27.79.3 28.29.9
QRS duration: mean (SD)* 125.130.6 126.531.2 123.631.3 125.730.3 125.030.1 121.429.2
Creatinine level: mean (SD)* 1.51.0 1.51.1 1.51.1 1.51.0 1.41.0 1.41.1
ICD indication*
Primary Prevention 20 413
(81.1%)
5150
(78.8%)
2560
(75.0%)
4526 (86.0%) 6634 (83.0%) 1543 (78.3%)
Secondary Prevention 4767 (18.9%) 1388
(21.2%)
854 (25.0%) 738 (14.0%) 1360 (17.0%) 427 (21.7%)
ICD type*
Single chamber 5553 (22.0%) 1115
(17.0%)
576 (16.9%) 1424 (27.1%) 1964 (24.6%) 474 (24.1%)
Dual chamber 10 101
(40.1%)
3039
(46.6%)
1708
(50.1%)
1646 (31.3%) 2915 (36.5%) 793 (40.3%)
Biventricular 9491 (37.7%) 2373
(36.4%)
1125 (3.0%) 2184 (41.6%) 3108 (38.9%) 701 (35.6%)
A indicates any antiplatelet agent; CABG, coronary artery bypass grafting; DA, dual antiplatelet therapy; EF, ejection function; ICD, implantable cardioverter defibrillator; MI, myocardial
infarction; NYHA, New York Heart Association; PCI, percutaneous coronary intervention.
*P<0.05.
Table 3. Hospital Characteristics Stratified by Medication Group
Total (n=25 180) A (n=6538) DA (n=3414) Warfarin (n=5264) A+Warfarin (n=7994) DA+Warfarin (n=1970) P Value
Geographic location
New England 1155 (4.6%) 263 (4.0%) 91 (2.7%) 233 (4.4%) 476 (5.9%) 92 (4.7%) <0.10
Mid-Atlantic 3429 (13.6%) 782 (12.0%) 406 (11.9%) 773 (14.7%) 1157 (14.5%) 311 (15.8%)
South Atlantic 5929 (23.5%) 1579 (24.2%) 816 (23.9%) 1297 (24.6%) 1794 (22.4%) 443 (22.5%)
East North Central 5050 (20.1%) 1284 (19.6%) 747 (21.9%) 964 (18.3%) 1641 (20.5%) 414 (21.0%)
East South Central 1926 (7.6%) 515 (7.9%) 284 (8.3%) 398 (7.6%) 571 (7.1%) 158 (8.0%)
West North Central 2427 (9.6%) 632 (9.7%) 301 (8.8%) 405 (7.7%) 899 (11.2%) 190 (9.6%)
West South Central 2525 (10.0%) 743 (11.4%) 382 (11.2%) 561 (10.7%) 669 (8.4%) 170 (8.6%)
Mountain 990 (3.9%) 230 (3.5%) 146 (4.3%) 212 (4.0%) 320 (4.0%) 82 (4.2%)
Pacific 1748 (6.9%) 510 (7.8%) 241 (7.1%) 420 (8.0%) 467 (5.8%) 110 (5.6%)
Profit type
Government 437 (1.7%) 107 (1.6%) 61 (1.8%) 93 (1.8%) 151 (1.9%) 25 (1.3%) <0.01
Private/community 21 945 (87.2%) 5789 (88.5%) 3021 (88.5%) 4653 (88.4%) 6798 (85.0%) 1684 (85.5%)
University 2798 (11.1%) 642 (9.8%) 332 (9.7%) 518 (9.8%) 1045 (13.1%) 261 (13.2%)
Community
Rural 3081 (12.2%) 861 (13.2%) 428 (12.5%) 563 (10.7%) 1019 (12.7%) 210 (10.7%) <0.01
Suburban 7535 (29.9%) 1911 (29.2%) 971 (28.4%) 1709 (32.5%) 2333 (29.2%) 611 (31.0%)
Urban 14 564 (57.8%) 3766 (57.6%) 2015 (59.0%) 2992 (56.8%) 4642 (58.1%) 1149 (58.3%)
A indicates any antiplatelet agent; DA, dual antiplatelet therapy.
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Assessment of Outcomes Using Inverse
Probability Weights
Comparison of groups using inverse probability–weighted
adjustment yielded findings consistent with the adjusted Cox
regression models. Patients discharged with DA, warfarin+A,
and warfarin+DA were independently associated with higher
bleeding risk 30 days following discharge (Table 7). The risk
of device-related bleeding was higher in patients discharged
with warfarin+A and warfarin+DA. The increased risk of
bleeding persisted 90 days following the procedure for
patients who were discharged on DA, warfarin+A, and
warfarin+DA (Table 7). The risk of device-related bleeding
remained elevated in patients discharged with DA, warfarin+A,
and warfarin+DA. DA was associated with an increased risk of
TEs and device-related complications within 90 days following
the procedure (Table 7). The risk of MACE was elevated
among patients discharged with A, DA, and DA+warfarin. The
elevated risk of MACE in these groups continued 90 days
following discharge (Table 7).
Discussion
In a large study of Medicare beneficiaries undergoing first
time ICD implantation, we found substantial variation across
hospitals in the use of antithrombotic agents. In addition, the
risk of postdischarge bleeding events varied by antithrombotic
strategy. The combinations of DA, warfarin+A, and warfa-
rin+DA were all associated with an increased risk of bleeding.
In contrast, there was no statistically significant difference in
the risk of TEs according to antithrombotic strategy used. The
findings from our study quantify the risks associated with
different approaches to antithrombotic therapy and may
identify potential opportunities for reducing complications and
improving outcomes among patients undergoing initial ICD
implantation.
There have been several studies that have examined
anticoagulation strategies in patients receiving heart-rhythm
devices. However, the majority of these studies have focused
on the perioperative complications related to antithrombotic
therapy. There is little data surrounding the role of postdis-
charge antithrombotic agents and short-term outcomes.
Although the majority of risk related to antithrombotic agents
is focused on the immediate perioperative period (ie, before
hospital discharge), a significant proportion of patients
develop complications after discharge. Our study is the first
study to demonstrate the risk of bleeding and TEs associated
with the choice of antithrombotic agents postdischarge.
Patients with CAD represent a large number of patients
who receive ICDs. Atrial fibrillation is common among patients
with CAD.12 The risk of TEs in patients with CAD and AF is
often managed by combining low-dose aspirin and warfarin
despite little evidence supporting this approach. Therefore,
the risk of bleeding must be carefully weighed against the risk
of TEs in this population, particularly in the periprocedural
period following ICD implantation. In our study, a significant
number of patients were on multiple antithrombotic medica-
tions, and we observed regional variation in patterns of
antithrombotic medications prescribed postdischarge. Fur-
thermore, this variation in antithrombotic medications was
not influenced by patients’ underlying risk of TEs. There was a
large of number of patients being discharged without warfarin
despite an elevated risk of TEs. The high risk of TEs evident by
CHADS2VASC ≥2 or higher was not predictive of discharge
warfarin, suggesting the possibility that the choice of
antithrombotic agents after ICD implantation is mainly driven
by the risk of bleeding rather than TEs. In our study, discharge
DA was associated with an increase in the risk of bleeding
without any associated reduction in TEs. This is consistent
with the results of several trials, which have established an
increase in the risk of bleeding without a significant reduction
in TEs in AF patients treated with DA therapy.2,13
Current guidelines recommend the use of “triple-therapy”
among patients with AF at moderate or high risk of TEs who
also have an indication for DA therapy.14 In our study,
patients discharged with “triple-therapy” were at increased
risk of bleeding, TEs, and MACE compared with other
strategies. These findings are consistent with previous
studies showing a higher rate of bleeding and cardiovascular
complications associated with triple therapy.15 It is likely that
many of the patients discharged on “triple-therapy” had a
compelling reason justifying the use of multiple agents
including the recent implantation of a drug-eluting stent.
Consistent with this hypothesis, we found that patients
discharged on “triple-therapy” were much more likely to have
undergone a PCI within 3 months of device implant. Never-
theless, we found that a substantial number of patients
discharged on “triple therapy” had no history of PCI or
Figure 2. Discharge medications according to CHADS2VASC
score. A indicates any antiplatelet agent; CHADS2 VASC, ; DA,
dual antiplatelet therapy; W, warfarin.
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myocardial infarction. Although these findings raise questions
about whether “triple-therapy” was in fact necessary, this
may simply reflect the fact that the registry may not capture
all indications for triple therapy in this population. Neverthe-
less, our study contributes to our understanding of this issue
by characterizing the risks associated with “triple-therapy.”
Given the excess risk of adverse outcomes associated with
use of “triple-therapy” following ICD implantation, practitio-
ners should take every effort to ensure that this risk is
clinically justified. Furthermore, our findings highlight the
need for additional studies to identify the best strategy for
balancing the risks and benefits of different antiplatelet and
anticoagulant drug combinations in this population. Recent
trials have shown an increase in the risk of bleeding with no
Figure 3. Selected predictors of postdischarge warfarin. BUN indicates blood urea nitrogen; CABG,
coronary artery bypass grafting; CHAD2SVASC, ; DM, diabetes mellitus; ESRD, end-stage renal disease;
HTN, hypertension; IHD, ischemic heart disease; MI, myocardial infarction; NA, Sodium; NIDCM,
nonischemic dilated cardiomyopathy; NYHA, New York Heart Association; PCI, percutaneous coronary
intervention; SBP, systolic blood pressure; SND, sinus node dysfunction; valve Sx, valve surgery.
Table 4. Number of Patients With Bleeding, Thromboembolic, and Device-Related Complications
Total (n=25 180) A (n=6538) DA (n=3414) Warfarin (n=5264) A+Warfarin (n=7994) DA+Warfarin (n=1970) P Value
Thirty-day outcomes
Bleeding 575 (2.3%) 142 (2.2%) 84 (2.5%) 90 (1.7%) 188 (2.4%) 71 (3.6%) 0.0001
Thromboembolic events 356 (1.4%) 89 (1.4%) 67 (2.0%) 79 (1.5%) 99 (1.2%) 22 (1.1%) 0.03
Device-related complications 605 (2.4%) 148 (2.3%) 95 (2.8%) 121 (2.3%) 190 (2.4%) 51 (2.6%) 0.5
Device-related bleeding 204 (0.8%) 44 (0.7%) 31 (0.9%) 30 (0.6%) 77 (1.0%) 22 (1.1%) 0.03
MACE 642 (2.5%) 197 (3.0%) 133 (3.9%) 93 (1.8%) 162 (2.0%) 57 (2.9%) <0.0001
Ninety-day outcomes
Bleeding 1147 (4.6%) 260 (4.0%) 166 (4.9%) 197 (3.7%) 379 (4.7%) 145 (7.4%) <0.0001
Thromboembolic events 705 (2.8%) 201 (3.1%) 126 (3.7%) 142 (2.7%) 189 (2.4%) 47 (2.4%) 0.001
Device-related complications 1072 (4.3%) 257 (3.9%) 163 (4.8%) 202 (3.8%) 360 (4.5%) 90 (4.6%) 0.096
Device-related bleeding 299 (1.2%) 63 (1.0%) 51 (1.5%) 44 (0.8%) 106 (1.3%) 35 (1.8%) 0.001
MACE 1766 (7.0%) 502 (7.7%) 339 (9.9%) 317 (6.0%) 459 (5.7%) 149 (7.6%) <0.0001
A indicates any antiplatelet agent; DA, dual antiplatelet therapy; MACE, major adverse cardiovascular events.
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difference in the risk of TEs or MACE in patients receiving
triple therapy compared to those receiving warfarin and
clopidogrel.15,16 These results are consistent with our find-
ings and suggest that double therapy may be an alternative to
triple therapy in patients receiving ICDs. There is a need for
randomized controlled trials that explore the role of different
combinations of antithrombotic drugs in patients following
ICD implantation.
Several aspects of our study warrant further consider-
ation. Our study cohort was limited to Medicare patients
older than 65, and this population may not be represen-
tative of all patients undergoing ICD implantation. However,
Table 5. Hazard Ratios for Medication Groups After Discharge
Warfarin A DA A+Warfarin DA+Warfarin
Bleeding
Thirty-day
Unadjusted Reference 1.27 (0.98 to 1.66) 1.45 (1.07 to 1.95) 1.38 (1.07 to 1.77) 2.13 (1.56 to 2.91)
Adjusted Reference 1.25 (0.96 to 1.62) 1.42 (1.05 to 1.91) 1.41 (1.10 to 1.82) 2.18 (1.60 to 2.98)
Ninety-day
Unadjusted Reference 1.07 (0.89 to 1.28) 1.31 (1.06 to 1.61) 1.27 (1.07 to 1.51) 2.00 (1.62 to 2.48)
Adjusted Reference 1.04 (0.87 to 1.26) 1.28 (1.04 to 1.58) 1.31 (1.10 to 1.55) 2.06 (1.66 to 2.55)
Thromboembolic events
Ninety-day
Unadjusted Reference 0.90 (0.67 to 1.23) 1.31 (0.94 to 1.81) 0.82 (0.61 to 1.11) 0.74 (0.46 to 1.19)
Adjusted Reference 0.88 (0.65 to 1.19) 1.22 (0.88 to 1.69) 0.83 (0.62 to 1.11) 0.73 (0.45 to 1.16)
Ninety-day
Unadjusted Reference 1.14 (0.92 to 1.41) 1.37 (1.08 to 1.75) 0.87 (0.70 to 1.09) 0.88 (0.63 to 1.23)
Adjusted Reference 1.10 (0.88 to 1.36) 1.25 (0.98 to 1.59) 0.89 (0.71 to 1.10) 0.86 (0.62 to 1.19)
Device-related complications
Thirty-day
Unadjusted Reference 0.98 (0.77 to 1.25) 1.22 (0.93 to 1.59) 1.03 (0.82 to 1.30) 1.13 (0.81 to 1.56)
Adjusted Reference 0.98 (0.77 to 1.25) 1.22 (0.93 to 1.59) 1.05 (0.84 to 1.32) 1.13 (0.81 to 1.57)
Ninety-day
Unadjusted Reference 1.02 (0.85 to 1.23) 1.25 (1.02 to 1.54) 1.18 (0.99 to 1.40) 1.19 (0.93 to 1.53)
Adjusted Reference 1.02 (0.85 to 1.22) 1.24 (1.01 to 1.52) 1.21 (1.01 to 1.43) 1.21 (0.94 to 1.55)
Device-related bleeding
Thirty-day
Unadjusted Reference 1.18 (0.74 to 1.88) 1.60 (0.97 to 2.64) 1.69 (1.11 to 2.58) 1.97 (1.13 to 3.41)
Adjusted Reference 1.17 (0.74 to 1.86) 1.58 (0.95 to 2.61) 1.74 (1.14 to 2.66) 2.01 (1.16 to 3.49)
Ninety-day
Unadjusted Reference 1.15 (0.78 to 1.70) 1.79 (1.20 to 2.68) 1.59 (1.12 to 2.26) 2.13 (1.37 to 3.23)
Adjusted Reference 1.13 (0.77 to 1.67) 1.74 (1.16 to 2.61) 1.63 (1.15 to 2.32) 2.16 (1.39 to 3.37)
MACE
Thirty-day
Unadjusted Reference 1.72 (1.34 to 2.20) 2.23 (1.71 to 2.90) 1.15 (0.89 to 1.48) 1.65 (1.18 to 2.29)
Adjusted Reference 1.68 (1.32 to 2.16) 2.16 (1.66 to 2.82) 1.22 (0.94 to 1.57) 1.75 (1.26 to 2.44)
Ninety-day
Unadjusted Reference 1.29 (1.12 to 1.49) 1.69 (1.45 to 1.97) 0.95 (0.83 to 1.10) 1.27 (1.04 to 1.54)
Adjusted Reference 1.26 (1.10 to 1.45) 1.65 (1.41 to 1.92) 1.01 (0.87 to 1.16) 1.35 (1.11 to 1.64)
A indicates any antiplatelet agent; DA, dual antiplatelet therapy; MACE, major adverse cardiovascular events.
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Table 6. Bleeding and Thromboembolic Events in Patients Treated and Not Treated With Warfarin
Warfarin No Warfarin P Value
Thirty-day outcomes
CHAD2VASC ≥2
Bleeding 19 (1.5%) 15 (1.7%) 0.79
Thromboembolic events 11 (0.9%) 9 (1.0%) 0.77
CHAD2VASC=3 to 5
Bleeding 254 (2.2%) 170 (2.3%) 0.60
Thromboembolic events 128 (1.1%) 91 (1.2%) 0.41
CHADSVASC ≥6
Bleeding 76 (3.1%) 41 (2.4%) 0.16
Thromboembolic events 61 (2.5%) 56 (3.3%) 0.15
Ninety-day outcomes
CHAD2VASC ≥2
Bleeding 41 (3.3%) 28 (3.1%) 0.83
Thromboembolic events 19 (1.5%) 15 (1.7%) 0.79
CHAD2VASC=3 to 5
Bleeding 539 (4.7%) 323 (4.4%) 0.40
Thromboembolic events 237 (2.0%) 202 (2.7%) <0.01
CHAD2VASC ≥6
Bleeding 141 (5.8%) 75 (4.4%) 0.04
Thromboembolic events 122 (5.1%) 110 (6.4%) 0.06
Table 7. Hazard Ratios for Medication Groups Using Inverse Probability Weights
Warfarin A DA A+Warfarin DA+Warfarin
Bleeding
Thirty-day Reference 1.21 (0.93 to 1.57) 1.39 (1.03 to 1.87) 1.32 (1.03 to 1.69) 2.03 (1.49 to 2.77)
Ninety-day Reference 1.04 (0.86 to 1.25) 1.29 (1.04 to 1.58) 1.24 (1.05 to 1.47) 1.96 (1.58 to 2.42)
Thromboembolic events
Thirty-day Reference 0.88 (0.65 to 1.19) 1.29 (0.93 to 1.79) 0.79 (0.59 to 1.06) 0.72 (0.44 to 1.15)
Ninety-day Reference 1.10 (0.89 to 1.36) 1.35 (1.06 to 1.71) 0.83 (0.67 to 1.03) 0.84 (0.60 to 1.17)
Device-related complications
Thirty-day Reference 0.97 (0.76 to 1.23) 1.19 (0.90 to 1.56) 1.03 (0.82 to 1.29) 1.10 (0.79 to 1.53)
Ninety-day Reference 1.03 (0.85 to 1.23) 1.25 (1.01 to 1.54) 1.18 (1.00 to 1.41) 1.19 (0.93 to 1.53)
Device-related bleeding
Thirty-day Reference 1.17 (0.74 to 1.86) 1.57 (0.95 to 2.61) 1.73 (1.14 to 2.63) 1.96 (1.13 to 3.40)
Ninety-day Reference 1.17 (0.80 to 1.72) 1.79 (1.19 to 2.69) 1.63 (1.15 to 2.32) 2.18 (1.39 to 3.40)
MACE
Thirty-day Reference 1.69 (1.33 to 2.16) 2.17 (1.66 to 2.83) 1.11 (0.86 to 1.43) 1.61 (1.16 to 2.24)
Ninety-day Reference 1.27 (1.10 to 1.46) 1.66 (1.42 to 1.93) 0.92 (0.80 to 1.07) 1.24 (1.02 to 1.51)
A indicates any antiplatelet agent; DA, dual antiplatelet therapy; MACE, major adverse cardiovascular events.
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this population is representative of the majority of patients
implanted with ICDs in the United States. We did not have
information about changes in medical regimens or medica-
tion compliance during the follow-up period. As such, we
restricted our primary analysis to short-term outcomes after
discharge. It is possible that unmeasured confounders may
have affected the results of our analysis, but we employed
rigorous analytical techniques in order to minimize the
effects of confounding on our results. The data regarding
the perioperative management of antithrombotic therapy
and International Normalized Ratio levels were not available
through the National Cardiovascular Data RegistryTM. There-
fore, we were not able to assess the role of perioperative
management of antithrombotic therapy and International
Normalized Ratio levels on outcomes. The data needed to
calculate the bleeding risk (ie, ATRIA bleeding risk score)
were not available through the ICD registry. Therefore, we
were not able to confirm high bleeding risk as the reason
for lack of postdischarge warfarin in patients with high risk
for TEs. Finally, our analysis did not include newer
anticoagulant and antiplatelet agents; therefore, these
results cannot be generalized to patients discharged with
novel antithrombotic agents.
In conclusion, we found that patients discharged with
warfarin alone have the lowest risk of bleeding after ICD
implantation. The concomitant use of antiplatelet therapy with
warfarin is associated with increased risk of bleeding without
a concomitant reduction in the risk of TEs. These data
underscore challenges associated with anticoagulation and
antiplatelet therapy following ICD implantation and suggest
the need for novel strategies to reduce the risk of compli-
cations in this population.
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